and be treated unnecessarily, we would state that these are reduced in number if the institution has expertise in RSV testing. Our greatest concern is that false-negative results fail to detect those patients that would be at risk of developing severe RSV disease and would go untreated, at least initially. We are more worried about the level of sensitivity of the test than about the level of specificity.
While we currently do not have any cost-benefit data to support the statement, in our opinion it appears to be more cost-effective to potentially treat a non-infected individual than to miss an infected individual resulting in severe RSV disease and potentially death.
Our study was a preliminary assessment of the potential benefit of RSV testing and early pre-emptive antiviral therapy in the prevention of severe RSV disease in bone marrow transplant patients. Clearly, additional larger studies will be needed to further enhance our understanding of this infection and the prevention of severe morbidity and mortality. While viral cultures would eliminate the problem of false-positive tests, in our opinion, it would delay the initiation of potentially life-saving therapy because of its poor sensitivity and the delay in generating results. In addition, rapid diagnostic testing has been found to be an invaluable tool in determining the need for cohorting infected individuals from those that are not infected. This would minimize the nosocomial spread of RSV.
4 Jacobsen and associates 4 found the direct fluorescent antibody assay to be sensitive, specific, and with high positive and negative predictive values.
Hepatitis B viremia in a patient with documented previous HBV immunity after autologous transplantation of highly purified PBSC
In the December 1999 (1) issue of BMT, Senecal et al 1 reported a patient with fatal acute hepatitis B after highdose therapy and autologous stem cell transplantation (SCT). This case was interesting because prior to transplant, the patient had a documented immune response against HBV (anti-HBs positive, anti-HBc positive, HBsAG negative), suggesting protective immunity against HBV after resolved HBV infection. The authors concluded that the course in this patient provides evidence for the possibility of reactivation of dormant HBV in spite of a protective immune status under the conditions of severe immunosuppression. We would like to describe a similar case to emphasize that HBV reactivation after autologous SCT can be of some importance in particular in patients reconstituted with heavily lymphocyte-depleted autografts.
In March 1999, a 51-year-old man with advanced chronic lymphocytic leukemia (B-CLL) underwent myeloablative treatment with 12 Gy fractionated total body irradiation and cyclophosphamide 120 mg/kg, followed by reinfusion of autologous PBSC. The autograft had been depleted of both T cells and B cells by sequential positive and negative It is unclear to what magnitude these problems will be resolved with newer technology such as polymerase chain reaction, but we are currently optimistic about their clinical utility. 
CD34
ϩ cell selection as previously described. 2 The residual T cell and B cell content of the inoculum was 0.26 and 0.31 ϫ 10 3 /kg, respectively. Previous cytotoxic treatment comprised six cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and two cycles of Dexa-BEAM (dexamethasone, BCNU, etoposide, ara-C, melphalan). During the mobilization and transplant procedures, the patient received a total of 16 blood units (red cells and platelets) from HBV-negative volunteer donors. Immunoglobulins were not administered. Four months after as well as immediately prior to transplant, HBV serology showed HBsAg negative, anti-HBs positive, anti-HBc-IgG positive, anti-HBc-IgM negative, compatible with protective immunity after a previous HBV infection. The transplant procedure was well tolerated and the patient presented with complete remission of the B-CLL at 3 months post transplant. HBV serology had remained unchanged. Four months later, however, the patient still had normal transaminases but showed the serological pattern of active HBV infection: HBsAg positive, anti-HBs negative, HBV-DNA positive (1.05 ϫ 10 8 copies/ml). A second analysis performed 2 weeks later yielded similar results. In December 1999, the patient was still alive and well without clinical or biochemical evidence of liver disease.
The serological course observed here documents recurrent HBV infection in an individual with established anti-HBV immunity. Since exogenous sources of infection could not be identified, the most probable explanation for this unusual pattern is reactivation of HBV persisting in the host. Apparently, the extensive in vivo and ex vivo depletion of lymphocytes in the context of autotransplantation of highly purified PBSC had eliminated T cell-mediated and humoral immune mechanisms responsible for the control of virus replication. In addition to the recommendation of Senecal et al who emphasized the necessity for careful monitoring of patients with positive HBV serology after SCT, the following conclusions can be drawn from this case. (1) Viral infection is a major cause of morbidity and mortality after allogeneic bone marrow transplantation (BMT) or peripheral blood stem cell transplantation. In contrast, patients undergoing autologous BMT or PBSCT are usually spared such infectious complications but viral complications may also occur even after autologous PBSCT, as described by us and by others, particularly after CD34-selected or T-depleted autologous PBSCT. 1, 2 It is not uncommon for patients to come to transplantation (autologous or allogeneic) with a serological status showing past HBV exposure. However, little is known about the risk of hepatitis reactivation after autologous PBSCT. Recently, a guide to managing patients and donors according to their respective serological status before transplantation was published.
3 These recommendations could apply to patients undergoing autologous PBSCT.
Dreger et al describe reactivation of HBV after purified PBSCT. The T-depletion of the graft may explain the different clinical courses between their patient and our patient. Clinical flares of hepatitis occur frequently at the time of immune reconstitution, 4 which is more delayed when ex vivo T-depletion of the graft is performed.
5
The recommendation of the authors stating that autografts from anti-HBs positive should be stored separately is questionable. If this procedure is recommended, it should, however, concern anti-HBc-positive subjects because antiHBc represents a marker of past HBV exposure rather antiHBs represents a marker of vaccination.
The third conclusion of the authors concerning antiviral prophylaxis for patients with past HBV exposure is also questionable. Indeed, antiviral therapy is recommended for HBV DNA-positive HBsAg chronic carriers, because antiviral drugs are only effective in the case of active HBV replication. This therapy has not been evaluated in acute hepatitis B or in the early events of a HBV reactivation. Furthermore, the risk of hepatitis B reactivation in patients previously infected by HBV after autologous PBSCT is probably very low considering the few cases reported in the literature.
In conclusion, we consider that patients undergoing autologous PBSCT or BMT with a previous history of HBV infection (anti-HBc positive, HBsAg negative) are at risk of viral reactivation after transplantation. This risk should be recognised by clinicians, and patients should be carefully monitored after transplantation, with frequent tests for transaminase levels and monitoring of hepatitis B serological status (test for HBV DNA and/or HBsAg). 
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